...
首页> 外文期刊>Journal of cardiac surgery. >Mitroflow and Perimount Magna 10 years outcomes a direct propensity match analysis to assess reintervention rates and long follow‐up mortality
【24h】

Mitroflow and Perimount Magna 10 years outcomes a direct propensity match analysis to assess reintervention rates and long follow‐up mortality

机译:Mitroflow和Perimount Magna 10年成果直接倾向匹配分析,以评估重新入住率和长期后续死亡率

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Objectives Biological valves are the most commonly used prostheses for aortic valve replacement (AVR) surgery in the UK. The aim of this retrospective observational study was to compare 10‐year outcomes of Perimount Magna and Mitroflow bioprosthesis implanted in a single center. Methods The medical records of patients undergoing AVR in Liverpool Heart and Chest Hospital between 1999 and 2014 were examined. All data were collected retrospectively, and a propensity match analysis was performed with a ratio 3:1 to analyze 10‐year outcomes. The primary outcomes were all‐cause mortality rates and aortic valve reintervention rates. Results A total of 2608 patients were included; Mitroflow bioprosthesis was used in 352 patients while Perimount Magna was used in 2256 patients. Median (interquartile range [IQR]) follow‐up for the entire data set was 6.95 (4.99, 9.69) years. After 10 years, the all‐cause mortality rate was higher in Mitroflow cohort 34.8% vs 14.7% ( P ??.001). A higher rate of aortic valve reintervention was observed in the Mitroflow cohort (4.7% vs 1%, P ??.001). Conclusions There were significant differences in survival and reintervention‐free survival rate between the two groups considered. The implant of the Perimount Magna valve seems to have a better short‐term and long‐term outcome over Mitroflow valve. Such results require larger studies to be validated.
机译:摘要目标生物阀是英国主动脉瓣膜置换(AVR)手术中最常用的假体。该回顾性观测研究的目的是比较植入单个中心的周边麦格纳和MITROFLOW生物调节的10年结果。方法研究了1999年至2014年间,1999年至2014年期间患有AVR患者AVR患者的病程。回顾性收集所有数据,并以比率3:1进行倾向匹配分析,以分析10年的结果。主要结果是全部导致死亡率和主动脉瓣重新入住率。结果共有2608名患者;在352名患者中使用MITROFLOW生物调节剂,而在2256名患者中使用了PERIMount MAINA。中位数(四分位数[IQR])整个数据集的随访时间为6.95(4.99,9.69)年。 10年后,MITROFLOW队列的全导致死亡率较高34.8%vs14.7%(P?& 001)。在MITROFLOW队列中观察到更高的主动脉瓣重新纳米术(4.7%Vs 1%,p≤001)。结论两组之间的存活率和无行动存活率存在显着差异。周边地区Magna阀的植入似乎在米特洛阀具有更好的短期和长期结果。这种结果需要验证更大的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号